Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[A 2024 inventory in oncology news].
Vignot S, Bellesoeur A, Bouleuc C, Cohen R, Courtier B, De Nonneville A, Delom F, Evrard S, Firmin N, Gandemer V, Khettab M, Magné N, Orbach D, Pellier I, Rodrigues M, Wislez M, Bay JO. Vignot S, et al. Among authors: bellesoeur a. Bull Cancer. 2024 Dec 16:S0007-4551(24)00464-8. doi: 10.1016/j.bulcan.2024.12.001. Online ahead of print. Bull Cancer. 2024. PMID: 39690092 Free article. Review. French.
Improving olaparib exposure to optimize adverse effects management.
Sterlé M, Puszkiel A, Burlot C, Pereira E, Bellesoeur A, De Percin S, Beinse G, Fumet JD, Favier L, Niogret J, Blanchet B, Royer B, Bengrine-Lefevre L, Schmitt A. Sterlé M, et al. Among authors: bellesoeur a. Ther Adv Med Oncol. 2024 Apr 24;16:17588359241248328. doi: 10.1177/17588359241248328. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38665845 Free PMC article.
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach.
Acramel A, Blondeel-Gomes S, Dupré M, Kayembe OT, Rochereau A, Escalup L, Desmaris R, Jourdan N, Cordary A, Vaflard P, Cottu P, Bellesoeur A. Acramel A, et al. Among authors: bellesoeur a. Br J Clin Pharmacol. 2024 May;90(5):1333-1343. doi: 10.1111/bcp.16020. Epub 2024 Feb 25. Br J Clin Pharmacol. 2024. PMID: 38403473
Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
Malhaire C, Selhane F, Saint-Martin MJ, Cockenpot V, Akl P, Laas E, Bellesoeur A, Ala Eddine C, Bereby-Kahane M, Manceau J, Sebbag-Sfez D, Pierga JY, Reyal F, Vincent-Salomon A, Brisse H, Frouin F. Malhaire C, et al. Among authors: bellesoeur a. Eur Radiol. 2023 Nov;33(11):8142-8154. doi: 10.1007/s00330-023-09797-5. Epub 2023 Jun 15. Eur Radiol. 2023. PMID: 37318605
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Farge D, et al. Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7. Lancet Oncol. 2022. PMID: 35772465 Free PMC article. Review.
Adverse events of targeted therapies approved for women's cancers.
Saint-Ghislain M, Levenbruck C, Bellesoeur A. Saint-Ghislain M, et al. Among authors: bellesoeur a. Int J Womens Dermatol. 2021 Oct 27;7(5Part A):552-559. doi: 10.1016/j.ijwd.2021.10.006. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35024412 Free PMC article. Review.
[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M. Salaün H, et al. Among authors: bellesoeur a. Bull Cancer. 2022 Jan;109(1):76-82. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17. Bull Cancer. 2022. PMID: 34799081 Review. French.
39 results